Closed Studies

Phase Ib Trial of 2nd Generation Designer T Cells in Metastatic Breast Cancer

Researcher

Richard Junghans, MD, PhD, Associate Professor of Medicine, Boston University School of Medicine, and Roger Williams Medical Center, Providence, Rhode Island

Study Review

This study at Boston University School of Medicine and Roger Williams Medical Center is investigating whether a high dose of designer T cells is better when given with or without interleukin 2 (IL2), a drug that is thought to stimulate the immune system. Study participants were randomly assigned to either receive modified T cells alone or modified T cells along with IL2. The researchers wanted to enroll up to 11 volunteers in the Providence area and they enlisted the Army of Women (AOW) to help support their recruitment efforts. The Call to Action for this study was sent to AOW members on July 13, 2011, and the researchers closed enrollment on March 31, 2015. The AOW provided them with 47 women who were interested in enrolling in the study.

 

 

En Español »